Tango Therapeutics, Inc. (TNGX)
| Market Cap | 4.10B +296.7% |
| Revenue (ttm) | n/a +48.3% |
| Net Income | -208.00M |
| EPS | -1.38 |
| Shares Out | 169.46M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,581,265 |
| Open | 24.86 |
| Previous Close | 25.50 |
| Day's Range | 24.15 - 25.87 |
| 52-Week Range | 7.69 - 34.39 |
| Beta | 1.22 |
| Analysts | Strong Buy |
| Price Target | 47.00 (+94.46%) |
| Earnings Date | Nov 9, 2026 |
About TNGX
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to ... [Read more]
Financial Performance
In 2025, Tango Therapeutics's revenue was $62.38 million, an increase of 48.29% compared to the previous year's $42.07 million. Losses were -$101.59 million, -22.03% less than in 2024.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for TNGX stock is "Strong Buy." The 12-month stock price target is $47.0, which is an increase of 94.46% from the latest price.
News
Tango Therapeutics price target lowered to $67 from $68 at H.C. Wainwright
H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Tango Therapeutics (TNGX) to $67 from $68 and keeps a Buy rating on the shares following the Q3 report.
Tango Therapeutics price target raised to $47 from $46 at JPMorgan
JPMorgan analyst Brian Cheng raised the firm’s price target on Tango Therapeutics (TNGX) to $47 from $46 and keeps an Overweight rating on the shares. The firm updated the company’s…
Tango Therapeutics Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
Updated combination data showed an 82% response rate in 22 pancreatic cancer patients, with durable responses and favorable tolerability. A frontline Phase III study is planned for H1 2027; second-line strategy and NSCLC development are key milestones.
Tango Therapeutics reports Q3 EPS (39c), consensus (35c)
“In 2026, Tango has made significant strides towards bringing vopimetostat to patients with pancreatic cancer,” said Malte Peters, President and Chief Executive Officer of Tango. “This progress is roo...
Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights
Promising Phase 1/2 data from combination study of vopimetostat plus daraxonrasib presented at 2026 ESMO Congress demonstrated 82% objective response rate (ORR) and 88% 9-month progression-free surviv...
Tango Therapeutics Quarterly report: Q3 2026
Tango Therapeutics has published its Q3 2026 quarterly earnings report on November 9, 2026.
Tango Therapeutics Earnings release: Q3 2026
Tango Therapeutics released its Q3 2026 earnings on November 9, 2026, summarizing the period's financial results.
Tango Therapeutics, Erasca initiate vopimetostat with ERAS-0015 study
Tango Therapeutics (TNGX) and Erasca (ERAS) announced that the Phase 1/2 study of oral PRMT5 inhibitor vopimetostat in combination with pan-RAS molecular glue ERAS-0015 in patients with MTAP-deleted p...
Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015
BOSTON and SAN DIEGO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to delivering breakthrough targeted therapies that ext...
Tango Therapeutics to Participate in Guggenheim's 3rd Annual Healthcare Innovation Conference
BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced that Malte Peters, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to ...
Tango Therapeutics added to Analyst Focus List at JPMorgan
JPMorgan analyst Brian Cheng added Tango Therapeutics (TNGX) to the firms’ Analyst Focus List while keeping an Overweight rating on the shares with a $46 price target The firm views…
Tango Therapeutics falls -12.6%
Tango Therapeutics (TNGX) is down -12.6%, or -$3.51 to $24.42.
Tango Therapeutics price target raised to $55 from $40 at Stifel
Stifel analyst Laura Prendergast raised the firm’s price target on Tango Therapeutics (TNGX) to $55 from $40 and keeps a Buy rating on the shares. The updated vopimetostat/daraxonrasib data and…
Tango Therapeutics falls -17.5%
Tango Therapeutics (TNGX) is down -17.5%, or -$4.89 to $23.04.
Tango Therapeutics Transcript: Study result
Vopimetostat plus daraxonrasib produced an 82% confirmed ORR and 88% 9-month PFS in MTAP-deleted pancreatic cancer, with a tolerability profile described as improved versus daraxonrasib alone. A 484-patient first-line Phase III trial is planned for H1 2027.
Tango Therapeutics Press release: Study result
Tango Therapeutics issued a press release on October 23, 2026, disclosing material business information to investors.
Tango Therapeutics Slides: Study result
Tango Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on October 23, 2026.
Tango announces results from obngoing Phase 1/2 study of vopimetostat
Tango Therapeutics (TNGX) announced promising results from its ongoing Phase 1/2 study of vopimetostat, an investigational PRMT5 inhibitor with first- and best-in-class potential, in combination with ...
Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy
82% objective response rate, median progression-free survival (PFS) not yet reached, and 9-month PFS-rate of 88% in patients with 2L/3L pancreatic cancer treated with vopimetostat plus daraxonrasib
Tango Therapeutics management to meet with Cantor
Breakfast Meeting to be held in Madrid on October 25 hosted by Cantor.
Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026
Company to host PDAC focused investor webcast on Friday, October 23, 2026, 7:30 am ET Company to host PDAC focused investor webcast on Friday, October 23, 2026, 7:30 am ET
Tango Therapeutics initiated with an Outperform at William Blair
William Blair analyst Alethia Young initiated coverage of Tango Therapeutics (TNGX) with an Outperform rating. Tango is a precision oncology company with an in-house CRISPR-based discovery engine that...
Tango Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Vopimetostat, a PRMT5 inhibitor, has shown unprecedented response rates in pancreatic cancer and is advancing toward regulatory approval, with a strong focus on combination therapies and expansion into lung cancer and glioblastoma. Mature data updates and regulatory strategy details are expected by year-end.
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (Tango Therapeutics or the Company) today announced that, effective September 1, 2026, the Compensation Committee of ...
Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (“Tango Therapeutics” or the “Company”) today announced that members of the management team are scheduled to particip...